Xin Lang Cai Jing·2025-12-19 02:27Core Viewpoint - Zhaoyan New Drug's stock price has shown significant volatility, with a year-to-date increase of 110.72%, but a recent decline in the last 60 days by 12.90% [1] Group 1: Stock Performance - As of December 19, Zhaoyan New Drug's stock price was 34.98 CNY per share, with a market capitalization of 26.217 billion CNY [1] - The stock has experienced a net inflow of 6.0604 million CNY from major funds, with large orders accounting for 22.37% of purchases and 20.10% of sales [1] - The stock has been on the "龙虎榜" three times this year, with the most recent occurrence on September 15 [1] Group 2: Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million CNY, a year-on-year decrease of 26.23%, while net profit attributable to shareholders increased by 214.79% to 80.7061 million CNY [2] - The company's main business revenue composition includes 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 57.61% to 96,500, with an average of 0 shares per shareholder [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huabao Zhongzheng Medical ETF and new entries from Guangfa Small Cap Growth Mixed Fund [3]